Sei Investments Co. Sells 2,115 Shares of Evolent Health, Inc. (NYSE:EVH)

Sei Investments Co. reduced its stake in Evolent Health, Inc. (NYSE:EVH) by 1.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,303 shares of the technology company’s stock after selling 2,115 shares during the quarter. Sei Investments Co.’s holdings in Evolent Health were worth $1,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Salem Investment Counselors Inc. raised its position in shares of Evolent Health by 53.0% during the 4th quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company’s stock valued at $3,939,000 after buying an additional 121,369 shares in the last quarter. Nordea Investment Management AB raised its position in Evolent Health by 7.0% during the fourth quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company’s stock valued at $1,469,000 after purchasing an additional 8,552 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in Evolent Health by 90.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company’s stock worth $9,036,000 after purchasing an additional 380,790 shares during the last quarter. Franklin Resources Inc. lifted its stake in Evolent Health by 40.8% during the third quarter. Franklin Resources Inc. now owns 909,776 shares of the technology company’s stock worth $24,682,000 after purchasing an additional 263,815 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Evolent Health by 181.3% in the 3rd quarter. Barclays PLC now owns 273,776 shares of the technology company’s stock worth $7,742,000 after purchasing an additional 176,445 shares in the last quarter.

Evolent Health Stock Down 1.0 %

NYSE EVH opened at $9.98 on Monday. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $33.63. The stock has a market capitalization of $1.16 billion, a PE ratio of -12.17 and a beta of 1.20. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The business’s 50-day moving average is $9.79 and its 200 day moving average is $14.61.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The business had revenue of $646.54 million during the quarter, compared to the consensus estimate of $650.92 million. Sell-side analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. JMP Securities reissued a “market outperform” rating and set a $12.00 price objective on shares of Evolent Health in a report on Friday, February 14th. Piper Sandler restated an “overweight” rating and issued a $16.00 price objective (down from $17.00) on shares of Evolent Health in a report on Friday, February 21st. Stephens cut their price objective on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 21st. Citigroup decreased their target price on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $15.00 price target on shares of Evolent Health in a research report on Friday, February 21st. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $17.71.

Insider Buying and Selling at Evolent Health

In related news, CEO Seth Blackley acquired 55,225 shares of the stock in a transaction on Thursday, March 6th. The stock was acquired at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the completion of the acquisition, the chief executive officer now directly owns 762,217 shares of the company’s stock, valued at approximately $6,867,575.17. This represents a 7.81 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Diane Holder bought 2,735 shares of Evolent Health stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of $9.33 per share, for a total transaction of $25,517.55. Following the acquisition, the director now directly owns 70,584 shares in the company, valued at approximately $658,548.72. This trade represents a 4.03 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 74,000 shares of company stock valued at $666,315. 1.60% of the stock is currently owned by company insiders.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.